Public health
Demonstrating whether new treatments work in clinical settings and investigating how they can best be incorporated into routine practice

Our public health cross-cutting theme brings together researchers, clinicians, practitioners and expertise in the design and evaluation of complex interventions, epidemiological studies, service evaluation and systematic reviews to deliver improved health and social care for patient and public benefit
Facilitated by a strong collaborative approach this research focuses on answering complex questions, and societal and global health challenges, particularly health inequality, in the areas of primary care, mental health and wellbeing, oral health, lifestyle risk & health and integrated care
Central to this approach, our Community and Primary Care research group, part of NIHR PenARC, connects researchers, expertise and activity across the University of Plymouth’s Institute of Health and Care Research, to investigate and evaluate treatments and preventative approaches across the healthcare sector
Trials and well-designed studies in our focus areas are supported by our UKCRC registered Peninsula Clinical Trials Unit (PenCTU) and our Medical Statistics teams. Current PenCTU facilitated studies within the public health theme include:
The cross-cutting public health theme encompasses:
Clinical, methodological trial and data management expertise to design, set up, conduct, analyse and publish high-quality clinical trials.Find out more about our UKCRC-registered Clinical Trials Unit
Quantitative statistical/data analysis and support, including study design, screening and risk assessment, across biomedical and clinical research, trials, consultancy and other services.Find out more about our dedicated Medical Statistics team
For more information about our public health research please contact the research Leads indicated for specific areas of interest.
General enquiries: primarycare@plymouth.ac.uk
IP, tech transfer and commercial enquiries: Dr Tom Nicholson (Research & Innovation Business Partner) or Dr David Mozley (IP Specialist Adviser)